在成功进行 III 期试验后，第 1 名意大利患者在肾癌显像剂 TLX250-CDx 指定患者计划中接受了给药。 1st Italian patient dosed in named patient program for kidney cancer imaging agent TLX250-CDx following successful Phase III trial.

Telix Pharmaceuticals 继 III 期 ZIRCON 研究取得成功之后，宣布在意大利的 TLX250-CDx 命名患者计划中对第一位患者进行了给药，TLX250-CDx 是一种研究性非侵入性碳酸酐酶 IX，靶向肾癌 PET 成像剂。 Telix Pharmaceuticals announces the first patient dosed in Italy's named patient program for TLX250-CDx, an investigational non-invasive carbonic anhydrase IX targeting PET imaging agent for kidney cancer, following successful Phase III ZIRCON study results. 意大利是继荷兰和美国之后第三个积极参与扩大准入计划的国家。 Italy is the third active country in the expanded access program after the Netherlands and the US. Telix 正在向包括 FDA 在内的主要商业管辖区提交监管申请。 Telix is submitting regulatory applications in key commercial jurisdictions, including the FDA.